Asahi Kasei Corporation

3407

JP3111200006

Diversified Chemicals

Market Closed - Japan Exchange Other stock markets 14:30:00 23/01/2026 HKT			5-day change	1st Jan Change
1,526.00 ^JPY	+1.19%		+0.76%	+9.86%

01-09	Zoll Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation Lifevest®? Wcd	CI
01-06	Tranche Update on Asahi Kasei Corporation's Equity Buyback Plan announced on November 5, 2025.	CI

Asahi Kasei Corporation authorizes a Buyback Plan.

Published on 11/05/2025 at 07:52 pm HKT

S&P Capital IQ

ASAHI KASEI CORPORATION

+1.19%

The Board of Directors of Asahi Kasei Corporation has authorized a buyback plan on November 5, 2025.

Latest news about Asahi Kasei Corporation

01-09	Zoll Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation Lifevest®? Wcd	CI
01-06	Tranche Update on Asahi Kasei Corporation's Equity Buyback Plan announced on November 5, 2025.	CI
12-24	Asahi Yukizai Corp to spend 17.5 billion yen to build new production base in Miyazaki, Japan for precision valves for semiconductor manufacturing equipment	RE
12-05	Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform	CI
12-05	Asahi Kasei Corp to discontinue production of hexamethylene diamine	RE
12-02	Asahi Kasei accelerates portfolio transformation with divestiture of Daramic lead battery separator business	RE
12-02	Kingswood Capital Management, LP acquired Daramic, LLC from Asahi Kasei Corporation.	CI
12-01	SENSIL by NILIT and ROICA by Asahi Kasei Collaborate to Reduce Apparel?s Footprint	CI
12-01	Asahi Kasei Advance and Teijin Frontier to integrate businesses, effective October 1, 2026	RE
12-01	Teijin Frontier Co., Ltd. concluded a basic agreement to acquire Asahi Kasei Advance Corporation from Asahi Kasei Corporation.	CI
11-17	Asahi Kasei: Filed litigation for infringement of patent rights of Ceolus in China	RE
11-12	Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience At CES 2026	CI
11-11	Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome At the American Society of Nephrology Kidney Week	CI
11-05	Asahi Kasei Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2026	CI
11-05	Asahi Kasei Corporation authorizes a Buyback Plan.	CI
11-05	Asahi Kasei Corporation announces an Equity Buyback for 45,000,000 shares, representing 3.31% for ¥40,000 million.	CI
11-05	Asahi Kasei's Net Income Climbs 10% in Fiscal H1	MT
11-05	Asahi Kasei Corp - to buy back up to 3.31% of shares worth 40 billion yen	RE
11-05	Asahi Kasei Licenses Novel Electrolyte Technology to EAS Batteries for the Market Launch of an Ultra-High-Power Cell	CI
11-05	Asahi Kasei Corp. Announces Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei?s Position in IgA Nephropathy Treatment	CI
23/10/25	Asahi Kasei Expanding Capacity to Manufacture System Components for Clean Hydrogen	CI
21/10/25	Japanese Shares Rise as Takaichi Becomes Japan's First Female Prime Minister	MT
21/10/25	Sawai Group Settles Patent Dispute with Asahi Kasei for 4 Billion Yen	MT
21/10/25	Sawai Group Holdings Co: Sawai Pharmaceutical Co has reached settlement with Asahi Kasei Pharma regarding patent infringement lawsuit concerning teriparatide for subcutaneous injection 56.5ug	RE
14/10/25	Asahi Kasei Corporation agreed to acquire 14.01% stake in R. C. Core Co., Ltd..	CI

Asahi Kasei Corp is a Japan-based company mainly engaged in the materials business, housing business and healthcare business. The Company operates through three business segments. The Materials segment provides styrene monomer, acrylonitrile, polyethylene, automotive-related fibers, electronic materials, mixed signal large scale integrated circuits (LSI), hall elements, deep ultraviolet light-emitting diodes (LEDs), pharmaceutical and food additives and others. The Housing segment provides construction contracting, renovation and other housing-related business, as well as lightweight aerated concrete (ALC), insulation materials and others. The Healthcare segment provides medical drugs, hemodialysis and apheresis related equipment, virus removal filters, cardiopulmonary resuscitation-related products and others. The Company also provides plant engineering, environmental engineering, various research and information provision businesses, and personnel dispatch and introduction services.

Employees

50,352

Sector

Diversified Chemicals

Calendar

02-04 - Q3 2025 Earnings Release

More about the company